Introduction Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory musculoskeletal disorder that manifests as peripheral arthritis, dactylitis, enthesitis and spondylitis. PsA results in ...

This review discusses the features of oligoarticular, polyarticular, systemic, and psoriatic JIA and enthesitis-related ...

Italy: A recent study published in RMD Open: Rheumatic & Musculoskeletal Diseases highlights a critical link between metabolic syndrome (MetS) and treatment resistance in patients with psoriatic ...

Metabolic syndrome is common in psoriatic arthritis and is a known risk factor for worse symptoms and poor treatment outcomes. This study sought to explore the syndrome's role in a more precisely ...

Market Implications: The ongoing study of LY3541860 could influence Eli Lilly’s stock performance and investor sentiment, particularly if the results show promise in treating rheumatoid arthritis.

"We're extremely pleased that the sam® 2.0 device has received the Arthritis Foundation's Ease of Use® certification." said George K. Lewis, founder and CEO of ZetrOZ Systems.

The sam® 2.0 has received the Arthritis Foundation’s Ease of Use® Certification signifying this is easier to use for people living with arthritis and chronic pain.

TRUMBULL, CONNECTICUT / ACCESS Newswire / June 24, 2025 / The sam®2.0 wearable ultrasound unit from ZetrOZ Systems has been documented in multiple clinical studies as an effective treatment for ...

Treatment of rheumatoid arthritis (RA) may differ among rheumatologists and currently, clear and consensual international recommendations on RA treatment are not available. In this paper ...